Published: March 11, 2010
The Annual General Meeting of Tripep AB
STOCKHOLM, Sweden - (BUSINESS WIRE) - Annual Report and discharge from liability The company's Income
Statement and Balance Sheet were adopted and the Board of Directors and
the Chief Executive Officer were discharged from liability for the
financial year 2009.
Election of Board of Directors and Chairman of the Board and
compensation to the Board Thomas Lynch, Anders Vahlne and Matti Sällberg
(all re-elected) and professor William Hall were appointed to the Board
of Directors.
Thomas Lynch was re-elected as Chairman of the Board.
The Meeting resolved that Thomas Lynch and William Hall shall each
receive a director's fee of 100,000 SEK.
Authorisation to issue shares, convertibles debentures and warrants The
Meeting authorized the Board of Directors to resolve, at one or more
occasions until the next Annual General Meeting and with pre-emption
right for the shareholders, to issue new shares, convertible debentures
and/or warrants with consideration in cash and/or in kind or by set-off
or otherwise with conditions.
New articles of association The Meeting resolved to adopt new articles
of association, whereby the company's name is changed to ChronTech
Pharma AB and the share capital shall be not less than 2.1 million SEK
and not more than 8.4 million SEK and the number of shares shall be not
less than 70 million and not more than 280 million.
Tripep (STO:TPEP) develops the therapeutic DNA-vaccines ChronVac-C and
ChronVac-B drugs against chronic hepatitis C virus and hepatitis B-virus
infections, i.e. chronic infections with jaundice causing viruses which
can lead to liver cirrhosis and liver cancer. Tripep has also developed
and further develops a patent pending new type of injection needle for a
more effective uptake of DNA vaccines. Tripep also have part ownership
in the wound healing therapy ChronSeal, and in the new platform
technology RAS. The Tripep share is admitted to trade on First North.
Remium AB is Certified Adviser for Tripep AB. For more information,
please visit: www.tripep.se
In the event of any discrepancy between the Swedish and English versions
of this press release, the Swedish version will take precedence.
This information was brought to you by Cision http://www.cisionwire.com
Tripep AB
Anders Vahlne, CEO and Head of Research
Tel: +46 8
5858 1313
mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se
Copyright © 2012, Business Wire, Inc., All rights reserved.
Copyright © 2012, NewsBlaze,
Daily News
Search News
